Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Pipeline Review, H1 2018, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.
Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sinusitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 4, 3 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sinusitis - Overview
Sinusitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Sinusitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sinusitis - Companies Involved in Therapeutics Development
AmpliPhi Biosciences Corp
F. Hoffmann-La Roche Ltd
Knopp Biosciences LLC
Kyorin Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
Merck & Co Inc
OptiNose US Inc
Pfizer Inc
Quorum Innovations LLC
Therabron Therapeutics Inc
Sinusitis - Drug Profiles
ABSA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexpramipexole dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lascufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1550 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06817024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Rhinosinusitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sinusitis - Dormant Projects
Sinusitis - Discontinued Products
Sinusitis - Product Development Milestones
Featured News & Press Releases
Feb 27, 2018: Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
Oct 30, 2017: Optinose Expands Leadership Team with Key Hires
Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal
Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences
Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials
Dec 19, 2016: AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients
Oct 25, 2016: AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis
Sep 20, 2016: AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients
Sep 16, 2016: OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis with and without Nasal Polyps
Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress
Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sinusitis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Sinusitis - Pipeline by AmpliPhi Biosciences Corp, H1 2018
Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Sinusitis - Pipeline by Knopp Biosciences LLC, H1 2018
Sinusitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Sinusitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Sinusitis - Pipeline by Merck & Co Inc, H1 2018
Sinusitis - Pipeline by OptiNose US Inc, H1 2018
Sinusitis - Pipeline by Pfizer Inc, H1 2018
Sinusitis - Pipeline by Quorum Innovations LLC, H1 2018
Sinusitis - Pipeline by Therabron Therapeutics Inc, H1 2018
Sinusitis - Dormant Projects, H1 2018
Sinusitis - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Sinusitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
